Evidence map›Paper›PMID 33832346›Full record

ArticleInternational journal of immunopathology and pharmacology

Fluoropyrimdine therapy induced alterations in interleukins expression in colorectal cancer patients.

Mariam A Fouad, Salem E Salem, Afaf S Osman, Doaa M Badr, Marwa M Hussein, Abdelrahman N Zekri, Hafez F Hafez, Mahmoud M Kamel, Samia A Shouman

Open access · goldAbstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mariam A FouadPharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt.ORCID https://orcid.org/0000-0003-0000-133X
Salem E SalemMedical Oncology Department, National Cancer Institute, Cairo, Egypt.
Afaf S OsmanMedical Pharmacology Department, Faculty of Medicine, Cairo University, Giza, Egypt.
Doaa M BadrPharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt.
Marwa M HusseinMedical Oncology Department, National Cancer Institute, Cairo, Egypt.
Abdelrahman N ZekriVirology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt.
Hafez F HafezPharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt.
Mahmoud M KamelClinical Pathology Department, National Cancer Institute, Cairo, Egypt.ORCID https://orcid.org/0000-0001-6264-6921
Samia A ShoumanPharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt.
Children Cancer Hospital · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study monitored the changes in the expression of inflammatory IL-6 and IL-1β during the treatment period of Fluoropyrimidine (FP) based therapy. RNA was extracted from the peripheral blood of 102 CRC patients before treatment with FP therapy, and from 48 and 32 patients after 3 and 6 months of treatment, respectively. The genetic transcription of IL-6 and IL-1β was determined by real time PCR. Patients were stratified according to their levels of IL-6 and IL-1β genes expression for subgroup and survival analyses. Baseline CRC patients showed overexpression of IL-6 and IL-1β compared to healthy control. FP therapy significantly induced IL-6 and IL-1β expression. Subgroup analysis showed that patients with right colon tumors had significant elevation in both IL-6 and IL-1β with FP therapy. FP therapy significantly induced IL-1β expression in patients ⩽45 years, smokers, with high baseline level of CA19.9, right colon tumors, low grade pathology, T3 tumors and positive lymph nodes. Survival analysis showed that baseline levels of interleukins expression had insignificant effect on overall survival and event free survival. FP therapy has an impact on the level of interleukins expression declared in certain clinicopathological subgroups of CRC patients, but without a prognostic significance on patients' survival.

Indexed as

AdultAgedAntineoplastic AgentsCapecitabineColorectal NeoplasmsFemaleHumansInterleukin-1betaInterleukin-6Kaplan-Meier EstimateMaleMiddle AgedOxaliplatinYoung AdultAntineoplastic AgentsCapecitabineIL1B protein, humanIL6 protein, humanInterleukin-1betaInterleukin-6Oxaliplatincolorectal cancerfluoropyrimidine therapyinterleukins expression

Identifiers

PMID33832346
PMCPMC8040557
OpenAlexW3146228735

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.